Literature DB >> 17760640

Ocular toxicity of fluoroquinolones.

Andrew M Thompson1.   

Abstract

The ocular toxicity of fluoroquinolones and the risks of their use in the treatment of ocular infection were reviewed. Systematic identification, selection, review and synthesis of published English-language studies relating to fluoroquinolone use and safety in animals and humans was conducted. Although not free of complications, fluoroquinolones are generally safe when used to treat ocular infection. Ocular toxicity appears to be dose-dependent and results from class-effects and specific fluoroquinolone structures. Phototoxicity and neurotoxicity have been reported, and toxic effects on ocular collagen may be associated with Achilles tendinopathy. Corneal precipitation may provide an advantageous drug depot but delay healing and result in corneal perforation in approximately 10% of cases. Although human toxicity studies are limited, the current recommended dose for intracameral injection of ciprofloxacin is less than 25 microg. Intravitreal injections of ciprofloxacin 100 microg, ofloxacin 50 microg/mL, trovafloxacin 25 microg or less, moxifloxacin 160 microg/0.1 mL or less and pefloxacin 200 microg/0.1 mL are considered safe.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17760640     DOI: 10.1111/j.1442-9071.2007.01552.x

Source DB:  PubMed          Journal:  Clin Exp Ophthalmol        ISSN: 1442-6404            Impact factor:   4.207


  22 in total

1.  Detection and prevention of ocular phototoxicity of ciprofloxacin and other fluoroquinolone antibiotics.

Authors:  Baozhong Zhao; Colin F Chignell; Mustapha Rammal; Frank Smith; Mary G Hamilton; Usha P Andley; Joan E Roberts
Journal:  Photochem Photobiol       Date:  2010-06-01       Impact factor: 3.421

2.  Comparison of moxifloxacin and levofloxacin in an epithelial disorder model using cultured rabbit corneal epithelial cell sheets.

Authors:  Taku Miyake; Norihiko Ito; Kazuki Tajima; Hiroshi Goto; Toshinori Furukawa
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-01-27       Impact factor: 3.117

Review 3.  Common eye infections.

Authors:  Stephanie Watson; Maria Cabrera-Aguas; Pauline Khoo
Journal:  Aust Prescr       Date:  2018-06-01

4.  Safety and tolerability of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis: data from six clinical and phase I safety studies.

Authors:  Timothy L Comstock; Michael R Paterno; Heleen H Decory; Dale W Usner
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

5.  Sustained ocular delivery of ciprofloxacin using nanospheres and conventional contact lens materials.

Authors:  Rahul Garhwal; Sally F Shady; Edward J Ellis; Jeanne Y Ellis; Charles D Leahy; Stephen P McCarthy; Kathryn S Crawford; Peter Gaines
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-03-13       Impact factor: 4.799

6.  Susceptibility of bacterial isolates to vancomycin and ceftazidime from patients with endophthalmitis: Is there a need to change the empirical therapy in suspected bacterial endophthalmitis?

Authors:  Ashok Kumar Reddy; Raja Rami Reddy; Muralidhar Rao Paruvelli; Srinivas Ambatipudi; Alka Rani; Sikander A K Lodhi; Juturi Maruthi Lokabhi Reddy; K Ramakanth Reddy; Niraj Pandey; Rituraj Videkar; Manish Kumar Sinha; Ajit Babu Majji; Nilanjana Deb-Jorder; Atul Kumar Sahu; Jyostna Myneni; Anina Abraham
Journal:  Int Ophthalmol       Date:  2014-11-11       Impact factor: 2.031

7.  Topical flagellin protects the injured corneas from Pseudomonas aeruginosa infection.

Authors:  Ashok Kumar; Nan Gao; Theodore J Standiford; Richard L Gallo; Fu-Shin X Yu
Journal:  Microbes Infect       Date:  2010-07-01       Impact factor: 2.700

8.  Comparative Evaluation of Antimicrobial, Antiamoebic, and Antiviral Efficacy of Ophthalmic Formulations.

Authors:  Ciro Caruso; Daniela Eletto; Alessandra Tosco; Martina Pannetta; Fabio Scarinci; Mario Troisi; Amalia Porta
Journal:  Microorganisms       Date:  2022-06-04

9.  A drug-eluting contact lens.

Authors:  Joseph B Ciolino; Todd R Hoare; Naomi G Iwata; Irmgard Behlau; Claes H Dohlman; Robert Langer; Daniel S Kohane
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-01-10       Impact factor: 4.799

10.  Development of novel in silico model to predict corneal permeability for congeneric drugs: a QSPR approach.

Authors:  Charu Sharma; Thirumurthy Velpandian; Nihar Ranjan Biswas; Niranjan Nayak; Rasik Bihari Vajpayee; Supriyo Ghose
Journal:  J Biomed Biotechnol       Date:  2011-02-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.